Abstract
To develop a model of severe desipramine cardiovascular toxicity and to determine whether partial neutralization of the antigen by desipramine-specific Fab antibody fragments ameliorates its cardiovascular effects. We administered desipramine to rats until the QRS interval tripled in duration and mean arterial pressure (MAP) was less than 100 mm Hg. Animals were then assigned to one of six groups: (1) no treatment, (2) normal saline solution control treatment (.9% NaCl infusion equal to the volume of Fab infusion), (3) nonimmune Fab control treatment (infusion of Fab equal to that in the 9.6% neutralization treatment), (4) 9.6% desipramine Fab (infusion of ovine desipramine Fab equal to 9.6% of an equimolar neutralization), (5) 19.2% desipramine Fab, and (6) 30.0% desipramine Fab. QRS-interval duration, heart rate, and MAP were recorded for 60 minutes. Animals in groups 1 through 3 demonstrated slow and incomplete improvement. Animals in groups 4 through 6 showed improvement in QRS-interval duration and heart rate within 4 minutes (P<.05) compared with untreated animals. A dose-response relationship was evident; animals given the highest dose of desipramine-specific Fab showed the greatest improvement. Partial neutralization of...Continue Reading
References
Nov 1, 1989·The Journal of Pharmacy and Pharmacology·M P TimsinaD S Hewick
Oct 1, 1985·The Journal of Pharmacy and Pharmacology·T H LinM Hanano
May 1, 1985·Journal of the American College of Cardiology·T L WengerT W Smith
Sep 1, 1994·The American Journal of Emergency Medicine·T L LitovitzR A Soloway
Citations
Jul 1, 1997·Critical Care Clinics·D D Vernon, M C Gleich
Oct 3, 2001·Academic Emergency Medicine : Official Journal of the Society for Academic Emergency Medicine·R E HillR C Dart
Mar 21, 2007·Critical Care : the Official Journal of the Critical Care Forum·Frédéric J BaudPascal Leprince
Jan 5, 2006·Toxicological Reviews·D Nicholas Bateman
Jun 8, 2010·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Nilüfer Yalindağ-OztürkBrett Giroir
Oct 20, 2010·Resuscitation·Jasmeet SoarJerry P Nolan
Oct 20, 2015·Resuscitation·Anatolij TruhlářUNKNOWN Cardiac arrest in special circumstances section Collaborators
Nov 24, 1999·Lancet·K HeardR C Dart
Jun 6, 2006·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Kennon HeardSuzanne B Ward
Nov 18, 1997·Human & Experimental Toxicology·C BismuthJ M Scherrmann
Nov 24, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Robert J Flanagan, Alison L Jones
Jan 5, 2006·Toxicological Reviews·Paul I DarganAlison L Jones
Oct 22, 2010·Circulation·Laurie J MorrisonUNKNOWN Advanced Life Support Chapter Collaborators
Oct 20, 2010·Resuscitation·Charles D DeakinUNKNOWN Advanced Life Support Chapter Collaborators